Nucala is the first and only anti-IL-5 add-on treatment approved in Canada that targets eosinophilic inflammation in adults with chronic rhinosinusitis with nasal polyps – GSK

Nucala (mepolizumab) is now approved in Canada as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by intranasal corticosteroids alone. This is the fourth approved indication for Nucala for Canadian patients with eosinophilic driven diseases and is the first and only anti-IL-5 add-on treatment that targets eosinophilic inflammation […]